NCT01323985 is a Phase 1 clinical trial of GSK2315698 in Amyloidosis, sponsored by GlaxoSmithKline.

Who is sponsoring NCT01323985?

NCT01323985 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT01323985?

Interventions in NCT01323985: GSK2315698, GSK2315698.

What condition does NCT01323985 study?

NCT01323985 studies Amyloidosis.

Is NCT01323985 still recruiting?

NCT01323985 is currently completed. Last updated 21 July 2017.

Last reviewed 2017-07-21 · How we verify

NCT01323985

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SAP Depleter Dose Escalation Study in Healthy Volunteers

Completed Phase 1 Last updated 21 July 2017

What this trial tests

Phase 1 trial testing GSK2315698 in Amyloidosis in 21 participants. Completed in 30 June 2011.

Timeline

6 January 2011

Primary endpoint
30 June 2011

30 June 2011

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	6 January 2011
Primary completion	30 June 2011
Estimated completion	30 June 2011
Sites	1 location across United Kingdom

Drugs / interventions tested

GSK2315698 — full drug profile →
GSK2315698 — full drug profile →

Conditions studied

Amyloidosis — all drugs for Amyloidosis →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 65, any sex, with Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to provide safety information and to define the optimal induction and short term maintenance regimen for GSK2315698 to deplete circulating SAP in healthy volunteers prior to assessing in patients

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis.
Nuvolone M, Nevone A, Merlini G. · · 2022 · cited 23× · PMID 36094752 · DOI 10.1007/s40259-022-00550-w
Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis.
Sahota T, Berges A, Barton S, Cookson L, et al · · 2015 · cited 9× · PMID 26225229 · DOI 10.1002/psp4.15

Verify or expand the search:

Other trials of GSK2315698

Trials testing the same drug.

NCT01777243 — A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis · Phase 1 · completed
NCT01406314 — SAP Depleter Dose Assessment Study in Patients · Phase 1 · completed

Other recruiting trials for Amyloidosis

Currently open trials in the same condition.

NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06974877 — Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure · Phase 1 · recruiting
NCT07081646 — A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido · Phase 1, PHASE2 · recruiting
NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
NCT06573723 — Institutional Registry of Rare Diseases · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01323985 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 21 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01323985.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing